2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow Recurrent Cholangiocarcinoma: new trials by email Literature Review of Recurrent Cholangiocarcinoma trials Research Report on Recurrent Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Active not recruiting | University of Kansas Medical Center | 15 | 2024-02-01 | 2026-02-24 |
| Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Glioblastoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 89 | 2019-01-30 | 2026-09-09 |
Cholangiocarcinoma (2) · Glioblastoma (1) · Glioma (1) · Klatskin Tumor (1)
Adenocarcinoma (2) · Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Astrocytoma (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Neuroectodermal Tumors (1)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · olaparib (1) · sacituzumab govitecan (1)
National Cancer Institute (NCI) (1) · University of Kansas Medical Center (1)
United States (2)
P30CA168524 (1), UM1CA186689 (1)